Biotech Values

[HS]

> Ridiculing a drug that is doing $1.5B a year in global sales and is number one in its category may win you some points on the ELN board on iVillage, but not here. <

Dew,
I still stand by my ridicule (based on inferior efficacy relative to Ty). Watch the next two years (I will). You still have not addressed that Copax took longer than Ty to achieve the $30 MIL mark. With BIIB pushing efficacy instead of risks this year you can bet they will eclipse the Copax market in 2009!

HS